Floatz logo

Carboplatin

Carcinoma Of Urethra

National Cancer Institute (NCI)Small moleculePhase 3Dormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Carcinoma Of Urethra cohort.

Asset / SponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
University of Southern California
Phase 3BBB
Vinblastine
University of Southern California
Phase 3BBB
METHOTREXATE
University of Southern California
Phase 3BBB
Adriamycin
University of Southern California
Phase 3BB
Docetaxel
Eli Lilly and Company
Phase 2B

View all 37 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaActive
A
Indicative · Phase 4
80 / 100
View asset →
primary peritoneal carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →
non-small cell squamous lung carcinomaActive
BBB
Indicative · Phase 3
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →